Evolving insights into the pathophysiology of heart failure with preserved ejection fraction

Current Cardiovascular Risk Reports

Volumn 3, Issue 5, 2009, Pages 374-379

  Najjar, Samer S ^a  

^a NATIONAL INSTITUTE ON AGING   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 82955173566     PISSN: 19329520     EISSN: 19329563     Source Type: Journal    
DOI: 10.1007/s12170-009-0054-3     Document Type: Article

References (42)

1. Owan TE, Hodge DO, Herges RM, et al.: Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 2006, 355: 251-259.
2. Bhatia RS, Tu JV, Lee DS, et al.: Outcome of heart failure with preserved ejection fraction in a population-based study. N Engl J Med 2006, 355: 260-269.
3. Bursi F, Weston SA, Redfield MM, et al.: Systolic and diastolic heart failure in the community. JAMA 2006, 296: 2209-2216.
4. Hunt SA, Abraham WT, Chin MH, et al.: 2009 Focused update incorporated into the ACC/AHA 2005 guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2009, 119: e391-e479.
5. Adams KF, Lindenfeld J, Arnold JM, et al.: HFSA 2006 Comprehensive Heart Failure Practice Guideline. J Card Fail 2006, 12: e1-e2.
6. Borlaug BA: Treatment of heart failure with preserved ejection fraction. Curr Treat Options Cardiovasc Med 2009, 11: 79-87.
7. Ahmed SH, Clark LL, Pennington WR, et al.: Matrix metalloproteinases/tissue inhibitors of metalloproteinases: relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease. Circulation 2006, 113: 2089-2096.
8. Cleland JG, Tendera M, Adamus J, et al.: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27: 2338-2345.
9. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362: 777-781.
10. Massie BM, Carson PE, McMurray JJ, et al.: Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med 2008, 359: 2456-2467.
11. Fonarow GC, Abraham WT, Albert NM, et al.: Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol 2008, 52: 190-199.
12. Hernandez AF, Hammill BG, O'Connor CM, et al.: Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009, 53: 184-192.
13. Zile MR, Baicu CF, Gaasch WH: Diastolic heart failure: abnormalities in active relaxation and passive stiffness of the left ventricle. N Engl J Med 2004, 350: 1953-1959.
14. Lam CS, Roger VL, Rodeheffer RJ, et al.: Cardiac structure and ventricular-vascular function in persons with heart failure and preserved ejection fraction from Olmsted County, Minnesota. Circulation 2007, 115: 1982-1990.
15. Zile MR, Brutsaert DL: New concepts in diastolic dysfunction and diastolic heart failure: Part II: causal mechanisms and treatment. Circulation 2002, 105: 1503-1508.
16. Klapholz M, Maurer M, Lowe AM, et al.: Hospitalization for heart failure in the presence of a normal left ventricular ejection fraction: results of the New York Heart Failure Registry. J Am Coll Cardiol 2004, 43: 1432-1438.
17. Melenovsky V, Borlaug B, Rosen B, et al.: Cardiovascular features of heart failure with pre-served ejection fraction versus non-failing hypertensive left ventricular hypertrophy in the urban Baltimore community. J Am Coll Cardiol 2007, 49: 198-207.
18. Yu CM, Lin H, Yang H, et al.: Progression of systolic abnormalities in patients with "isolated" diastolic heart failure and diastolic dysfunction. Circulation 2002, 105: 1195-1201.
19. Wang J, Khoury DS, Yue Y, et al.: Preserved left ventricular twist and circumferential deformation, but depressed longitudinal and radial deformation in patients with diastolic heart failure. Eur Heart J 2008, 29: 1283-1289.
20. Baicu CF, Zile MR, Aurigemma GP, Gaasch WH: Left ventricular systolic performance, function, and contractility in patients with diastolic heart failure. Circulation 2005, 111: 2306-2312.
21. Kawaguchi M, Hay I, Fetics B, Kass DA: Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: implications for systolic and diastolic reserve limitations. Circulation 2003, 107: 714-720.
22. Maurer MS, King DL, El-Khoury Rumbarger L, et al.: Left heart failure with a normal ejection fraction: identification of different pathophysiologic mechanisms. J Card Fail 2005, 11: 177-187.
23. Aurigemma GP, Zile MR, Gaasch WH: Contractile behavior of the left ventricle in diastolic heart failure: with emphasis on regional systolic function. Circulation 2006, 113: 296-304.
24. De Keulenaer GW, Brutsaert DL: Diastolic heart failure: a separate disease or selection bias?Prog Cardiovasc Dis 2007, 49: 275-283.
25. Maurer MS, Kronzon I, Burkhoff D: Ventricular pump function in heart failure with normal ejection fraction: insights from pressure-volume measurements. Prog Cardiovasc Dis 2006, 49: 182-195.
26. Maurer MS, Burkhoff D, Fried LP, et al.: Ventricular structure and function in hypertensive participants with heart failure and a normal ejection fraction: the Cardiovascular Health Study. J Am Coll Cardiol 2007, 49: 972-981.
27. Najjar SS, Schulman SP, Gerstenblith G, et al.: Age and gender affect ventricular-vascular coupling during aerobic exercise. J Am Coll Cardiol 2004, 44: 611-617.
28. Kitzman DW, Higginbotham MB, Cobb FR, et al.: Exercise intolerance in patients with heart failure and preserved left ventricular systolic function: failure of the Frank-Starling mechanism. J Am Coll Cardiol 1991, 17: 1065-1072.
29. Borlaug BA, Melenovsky V, Russell SD, et al.: Impaired chronotropic and vasodilator reserves limit exercise capacity in patients with heart failure and a preserved ejection fraction. Circulation 2006, 114: 2138-2147.
30. Borlaug BA, Kass DA: Ventricular-vascular interaction in heart failure. Heart Fail Clin 2008, 4: 23-36.
31. Najjar SS, Lakatta EG: Aging of the heart and arteries: relevance to cardiovascular disease. In Contemporary Cardiology: Cardiovascular Diseases in the Elderly. Edited by Gerstenblith G. Totowa, NJ: Humana Press 2005: 1-50.
32. Laurent S, Boutouyrie P, Asmar R, et al.: Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension. 2001, 37: 1236-1241.
33. Sutton-Tyrrell K, Najjar SS, Boudreau RM, et al.: Elevated aortic pulse wave velocity, a marker of arterial stiffness, predicts cardiovascular events in well-functioning older adults. Circulation 2005, 111: 3384-3390.
34. Mattace-Raso FU, van der Cammen TJ, Hofman A, et al.: Arterial stiffness and risk of coronary heart disease and stroke: the Rotterdam Study. Circulation 2006, 113: 657-663.
35. Willum-Hansen T, Staessen JA, Torp-Pedersen C, et al.: Prognostic value of aortic pulse wave velocity as index of arterial stiffness in the general population. Circulation 2006, 113: 664-670.
36. Najjar SS, Scuteri A, Shetty V, et al.: Pulse wave velocity is an independent predictor of the longitudinal increase in systolic blood pressure and of incident hypertension in the Baltimore Longitudinal Study of Aging. J Am Coll Cardiol 2008, 51: 1377-1383.
37. Waldstein SR, Rice SC, Thayer JF, et al.: Pulse pressure and pulse wave velocity are related to cognitive decline in the Baltimore Longitudinal Study of Aging. Hypertension 2008, 51: 99-104.
38. O'Rourke MF, Safar ME: Relationship between aortic stiffening and microvascular disease in brain and kidney. Cause and logic of therapy. Hypertension 2005, 46: 200-204.
39. Hundley WG, Kitzman DW, Morgan TM, et al.: Cardiac cycle-dependent changes in aortic area and distensibility are reduced in older patients with isolated diastolic heart failure and correlate with exercise intolerance. J Am Coll Cardiol 2001, 38: 796-802.
40. Little WC, Zile MR, Kitzman DW, et al.: The effect of alagebrium chloride (ALT-711), a novel glucose cross-link breaker, in the treatment of elderly patients with diastolic heart failure. J Card Fail 2005, 11: 191-195.
41. Sunagawa K, Maughan WL, Burkhoff D, Sagawa K: Left ventricular interaction with arterial load studied in isolated canine ventricle. Am J Physiol Heart Circ Physiol 1983, 245: H773-H780.
42. Chantler PD, Lakatta EG, Najjar SS: Arterial-ventricular coupling: mechanistic insights into cardiovascular performance at rest and during exercise. J Appl Physiol 2008, 105: 1342-1351.